Resistance to Targeted Agents Used to Treat Paediatric ALK-Positive ALCL.
MetadataShow full item record
Hare, L., Burke, G. A., & Turner, S. D. (2021). Resistance to Targeted Agents Used to Treat Paediatric ALK-Positive ALCL.. Cancers (Basel), 13 (23) https://doi.org/10.3390/cancers13236003
Non-Hodgkin lymphoma (NHL) is the third most common malignancy diagnosed in children. The vast majority of paediatric NHL are either Burkitt lymphoma (BL), diffuse large B-cell lymphoma (DLBCL), anaplastic large cell lymphoma (ALCL), or lymphoblastic lymphoma (LL). Multi-agent chemotherapy is used to treat all of these types of NHL, and survival is over 90% but the chemotherapy regimens are intensive, and outcomes are generally poor if relapse occurs. Therefore, targeted therapies are of interest as potential solutions to these problems. However, the major problem with all targeted agents is the development of resistance. Mechanisms of resistance are not well understood, but increased knowledge will facilitate optimal management strategies through improving our understanding of when to select each targeted agent, and when a combinatorial approach may be helpful. This review summarises currently available knowledge regarding resistance to targeted therapies used in paediatric anaplastic lymphoma kinase (ALK)-positive ALCL. Specifically, we outline where gaps in knowledge exist, and further investigation is required in order to find a solution to the clinical problem of drug resistance in ALCL.
nucleophosmin1-anaplastic lymphoma kinase, anaplastic large cell lymphoma, resistance, chemotherapy, paediatric cancer
External DOI: https://doi.org/10.3390/cancers13236003
This record's URL: https://www.repository.cam.ac.uk/handle/1810/331702